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ABSTRACT  
Background and aims 
Tuberculosis (TB) patients who quit smoking have much better disease outcomes than those 
who continue to smoke. Behavioural support combined with pharmacotherapy is the most 
effective strategy in helping people to quit, in general populations. However, there is no 
evidence for the effectiveness of this strategy in TB patients who smoke. We will assess the 
safety, effectiveness and cost-effectiveness of cytisine – a low-cost plant-derived nicotine 
substitute – for smoking cessation in TB patients compared with placebo, over and above 
brief behavioural support.  
Design 
Two-arm, parallel, double-blind, placebo-controlled, multi-centre (30 sites in Bangladesh 
and Pakistan), individually randomised trial. 
Setting 
TB treatment centres integrated into public health care systems in Bangladesh and 
Pakistan. 
Participants 
Newly diagnosed (in the last four weeks) adult pulmonary TB patients who are daily 
smokers (with or without dual smokeless tobacco use) and are interested in quitting (n= 
2,388).  
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Measurements 
The primary outcome measure is biochemically verified continuous abstinence from 
smoking at six months post-randomization, assessed using Russell Standard criteria. The 
secondary outcome measures include continuous abstinence at 12 months, lapses and 
relapses; clinical TB outcomes; nicotine dependency and withdrawal; and adverse events.  
Comments 
This is the first smoking cessation trial of cytisine in low- and middle-income countries 
evaluating both cessation and tuberculosis (TB) outcomes. If found effective, cytisine could 
become the most affordable cessation intervention to help TB patients who smoke.  
Keywords 
Tobacco cessation, Smoking cessation, Cytisine, Low-and-Middle Income Countries, 
placebo-controlled randomised trial, Tuberculosis, Bangladesh, Pakistan. 
 
INTRODUCTION 
Tuberculosis (TB) is a widespread and, in many cases, fatal infectious disease. About 85% of 
TB deaths occur in the low- and middle- income countries (LMICs) in African and the 
South-East Asian regions (1). Evidence suggests that smoking increases the risk of 
developing TB disease (2-4) and leads to poorer outcomes in those TB patients who 
continue to smoke (3, 5). Of the 10.4 million incident cases of TB in 2016, an estimated 0.8 
million were attributable to smoking (1).  
Newly diagnosed TB patients experience high levels of anxiety, including fear of death and 
worries about infecting others. This provides a ‘teachable moment’ that health professionals 
can use to offer smoking cessation advice (6). ‘Teachable moments’ are conceptualised as 
events or sets of circumstances that can lead patients to alter their health behaviour 
positively (7). Moreover, the potential health benefits of cessation are greater among TB 
patients than among other smokers, as most of the tobacco-induced immunological 
abnormalities in TB patients reverse within six weeks of quitting (8). It therefore makes 
sense to offer smoking cessation to TB patients who smoke, as part of routine care, although 
this opportunity is rarely taken (9, 10).  
There is substantial evidence on the effectiveness of behavioural support (BS) and a range of 
pharmacotherapies available for smoking cessation (11-14). Whilst these medications, 
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particularly Nicotine Replacement Therapy and Varenicline, are widely recommended, their 
costs prohibit their use in LMICs. Cytisine - a plant-derived pharmacotherapy 
(manufactured as Tabex and Desmoxan) - has recently gained recognition as a safe, 
efficacious and affordable cessation aid (14, 15). Although cytisine is not licensed in most 
countries outside Eastern Europe (16, 17), recent studies (18, 19) highlight its potential for 
use in LMICs (14). Particularly attractive is its lower cost (US$20 to US$30 for 25 days) in 
comparison to NRT (US$112 to US$685 for 8 to 10 weeks) and Varenicline (US$474 to 
US$501 for 12 weeks) (20). Cytisine was therefore chosen as a suitable medication to trial as 
part of a project called ‘TB & Tobacco’; - an EU- funded study of tobacco cessation in TB 
patients in South Asia. 
The TB & Tobacco study investigates an innovative approach to improve lung health in 
LMICs by integrating inexpensive tobacco cessation strategies of proven efficacy into TB 
programmes. The project has two goals: (i) the effectiveness goal – the TB & Tobacco trial, 
and (ii) the implementation goal – BS implementation, its process and context evaluation. This 
protocol focuses on the effectiveness goal.  
The primary aim of this trial is to evaluate the effectiveness and cost-effectiveness of 
cytisine for smoking cessation among TB patients. Secondary aims include assessment of its 
effectiveness and cost-effectiveness in improving TB outcomes; differential effect by the 
form of tobacco used; effect moderators - TB severity, socio-economic status (SES), gender 
and age; adverse effects; nicotine dependency, withdrawals; and process of delivery. An 
overview of all objectives is listed in Table 1. [Insert table 1 here] 
METHODS 
Design 
This is a phase III, double-blind, individually randomised, parallel-group placebo-controlled 
trial. Participants will receive random allocation in a 1:1 ratio to cytisine or matching 
placebo treatment. Figure 1 illustrates the TB & Tobacco trial flowchart. [Insert Figure 1 
here]. 
Participants 
Newly diagnosed (within the last four weeks) adult pulmonary TB patients who smoke 
(with or without dual smokeless tobacco use) on a daily basis, wish to quit, and are able to 
provide consent. Table 2 presents participants’ eligibility criteria. [Insert Table 2 here].  
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Participants will not receive financial incentives except nominal travel costs for any follow-
up visits that fall outside routine TB care. The trial will be conducted at 17 sites in 
Bangladesh and 13 in Pakistan. Sites are designated TB treatment centres run by the 
respective National TB control Programmes (NTP). Supplement 1 lists the trial sites.  
Interventions 
All trial participants will receive brief BS for smoking cessation integrated within the more 
broad advice offered to TB patients to manage their TB and adhere to TB medication. Two 
face-to-face BS sessions will be delivered at Day 0 and Day 5 (for 10 minutes and 5 minutes, 
respectively). Further encouragement and support is offered, if needed, at the Week 5 visit. 
BS materials have been translated and adapted to the local context in Bangladesh and 
Pakistan. The findings relating to the implementation goal of the ‘TB & Tobacco project’ 
will inform further adaptation of the BS, to enable scale up and sustainable delivery within 
National TB Programmes (See supplements 2 & 3 for details on BS).  
Randomised patients will receive either cytisine (as Desmoxan) (active arm), or matching 
placebo (control arm) in their Investigational Medicinal Product (IMP), which is 
manufactured as 1.5 mg hard capsules for oral administration, with a shelf life of two years. 
Patients receive seven days’ IMP on the day of enrolment and are expected to return on the 
fifth day (+2 days), coinciding with their quit date, when they are dispensed another 18 
days’ supply by the study researcher.  
Cytisine 
Cytisine, a partial agonist of nicotinic acetylcholine receptors, is pharmacologically similar 
to Varenicline (Chantix). With a half-life of 4.8 hours, cytisine is rapidly eliminated from the 
body (20). The standard regimen is a 25-day course, gradually reducing from six capsules a 
day to one capsule on the last day by the end of the treatment period, with a quit date set for 
day five (15). Table 3 presents the dosing schedule for the cytisine. [Insert Table 3 here]. 
Placebo 
Patients in the control arm will receive the placebo in exactly the same manner as cytisine. 
A checking exercise was carried out using paired samples of capsules to ensure that placebo 
pills were unrecognizable. Blinded York Trials Unit staff could not distinguish between 
placebo and active pills based on their appearance, smell or taste.  
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Outcomes 
Patients will have assessments on day 0 (baseline), day 5, weeks 5, 9 and 12, and months 6 
and 12. These time-points, except day 5 and month 12, were chosen to correspond with 
routine TB care visits. The day 5 visit is to monitor for any adverse drug reaction and the 
month 12 visit is to assess longer-term smoking cessation and any TB relapses. Table 4 
provides the schedule for trial participants from initial eligibility screening, dispensing of 
IMP and the data collection/assessments. [Insert Table 4 here]. 
Primary outcome measure 
The primary outcome is biochemically-verified continuous smoking abstinence at six 
months post-randomization as per Russell Standard (21); self-report of not using more than 
five cigarettes/bidis/water pipe sessions/chewing tobacco products from the quit date (5 + 
2 days) supported by a negative exhaled carbon monoxide (CO <10 ppm) test at six months, 
using a Micro MC02 CO Monitor (CareFusion UK Ltd). In concomitant smokeless tobacco 
users, instead of CO, a cotinine dipstick test (OneStep Urine Test Strip, sensitivity 200 
ng/ml, supplied by Home Health UK) will be used for biochemical verification of abstinence. 
An elevated CO or cotinine level will always take precedence over patient’s self-reported 
abstinence. In the analysis, patients will be considered smokers if their smoking status could 
not be determined. 
Although smoking status is assessed both at six months and at 12 months’ time-points, in 
the interest of better retention rates, primary outcome is measured at 6-months. 
Secondary outcome measures 
Abstinence, lapses and relapses 
Continuous abstinence at 12 months (same definition as for primary outcome at six months). 
Point abstinence, defined as a self-report of not using tobacco in the previous 7-days at 
weeks 5 and 12, and at months 6 and 12 (abstinence is verified biochemically at months 6 
and 12, only). In addition, early-lapse, late-lapse, early-relapse and late-relapse assessed 
according to the definitions presented in Table 5. [Insert Table 5 here] 
TB outcomes 
Assessment for the impact of smoking cessation on TB outcomes includes clinical TB score 
(22-24); sputum conversion results; chest X-ray grading (normal, minimal, moderately 
advanced or far advanced TB) (25); adherence to TB treatment; and standard TB treatment 
outcomes (success, failure, default, relapse or death). The researchers will assess signs and 
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symptoms for TB score (supported by the clinical team), while routine reporting on TB 
cards/registers maintained by the TB programme will provide the remaining TB outcomes. 
Table 6 presents the definitions of the TB outcomes. [Insert Table 6 here] 
Nicotine Dependency  
Assessment of nicotine dependency includes translated versions of the Mood and Physical 
Symptoms Scale (MPSS) (26), the Strength of Urges To Smoke (SUTS) scale (27) and the 
Heaviness of Smoking Index (HSI) (28, 29), in Bangla and Urdu. 
Adverse Events  
Table 7 presents definitions of adverse events (AEs), which will be collected up to week 9 
and self-reports recorded on the ‘AEs review’ checklist in the patient case-report form that 
is compiled from the Summary of Product Characteristics for Desmoxan and previous 
relevant Randomised Controlled Trials (RCT) (16, 19, 30, 31). The checklist includes 
symptoms relating to possible cytisine side effects: nausea, diarrhoea, dry mouth, epigastric 
pain, headache, insomnia, abnormal dreams, irritability, anxiety, tachycardia, 
musculoskeletal pain. A clinical review will be required for patients reporting any moderate-
to-severe symptoms, classified using the Common Terminology Criteria for Adverse Events 
(CTCAE) (32). A site-designated clinician, trained in study-related AEs will review and 
determine the severity and relationship of the event to the study treatment.  
The researcher at each site will notify all serious adverse events to the country coordinating 
office within 24 hours of becoming aware of an event, who will in turn notify the York trial 
team within (a further) 24 hours. Medically qualified staff at the country coordinating office 
will confirm ‘causality’ and ‘expectedness’ and code these events using the Medical 
Dictionary for Regulatory Activities (MedDRA) (33). [Insert Table 7 here] 
Adherence 
Adherence will be monitored using a questionnaire at Day 5 and each subsequent follow-up 
appointment, as well as by counting empty cells in the blister packets (Day 5 and Week 5). 
Dosing schedule cards will be provided to help maximise adherence.  
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Process evaluation 
A mixed methods process evaluation will assess reach, dose received, dose delivered and 
fidelity for trial and BS components; the protocol is submitted separately for publication.  
Sample size 
The sample size is based on known cessation rates for BS and previously observed group 
differences using cytisine. The Action for Stopping Smoking In Suspected TB (ASSIST) 
trial (based on 1955 patients in Pakistan) reported that 41% of regular smokers with 
presumptive TB sustained biochemically verified smoking cessation at six months after 
random allocation to BS (34). Previous RCTs of cytisine have shown increases of 6-7% 
(differences in absolute percentages) for sustained cessation (16, 19, 30). To detect an 
increase of 6% in the six-month abstinence rate for the addition of cytisine to BS, from 41% 
to 47%, with 80% power, testing at the 5% significance level, requires primary outcome data 
for a total of 2,148 participants (1,074 in each arm). The ASSIST trial reported missing 
primary outcome data on 5.5% of participants. Assuming a more conservative attrition rate 
of 10% gives a target recruitment of 2,388 participants (1,194 in each arm).   
Randomisation  
Allocation to the trial arms is by pre-prepared block randomisation lists for each country, 
generated by the trial statistician. IMP packs are sequentially labelled in their randomised 
order and distributed to trial sites in batches. Once a patient has consented to participate, 
the researcher at the site calls the country coordinating office to obtain the patient’s 
allocated trial number and confirm the next IMP pack number in the sequence to dispense 
to the patient.  
Blinding 
Patients, clinical team and researchers will remain blind to treatment allocation. To ensure 
double blinding, IMP packs appear identical and only the code-break envelopes prepared 
separately for each trial number could ascertain treatment allocation. In an emergency, any 
request to un-blind must be authorised by a clinician or senior trial staff. Each country 
coordinating office will be contactable by in- and out-of-office hours contact numbers; the 
contacted staff will need to travel to the office in order to access the code-break envelopes 
and follow the procedure for un-blinding as per manual of operations.  
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Statistical methods 
Analyses will be based on intention-to-treat, analysing participants in the arm to which they 
were randomised. Significance tests will be two-sided at the 5% level. Baseline 
characteristics (see Table 4 for details) will be presented descriptively to assess balance 
between cytisine and placebo arms in terms of: (a) ecologic factors at the TB treatment 
centre level; and (b) individual factors at patient level. 
Primary analysis 
Missing primary outcome data will be treated as a negative outcome, i.e. continuous 
smoking (21). Agreement between self-reported and biochemically-verified abstinence will 
be reported by trial arm. The number and proportion of abstinent patients will be reported 
by trial arm, and group differences will be illustrated by the risk difference and relative risk 
with associated 95% CIs and p-values. Abstinence rates will be compared between the active 
and the control arms, using logistic regression. Trial sites will be included as a random 
effect using robust standard errors.  
Secondary outcomes analysis 
The primary analysis will be repeated for the following secondary outcomes: continuous 
abstinence for 12 months, point abstinence at week 5 and 12, month 6 and 12, as well as 
early and late lapses and relapses (Table 5). Point abstinence will be plotted over time. TB 
outcomes of TB score, sputum conversion, x-ray assessment, treatment adherence and 
programme outcomes, as well as withdrawal and dependency, as measured by MPSS and 
SUTS, will be analysed using appropriate statistical models for continuous or categorical 
data using all available time points. 
The total number of AEs, the number of patients with any AE and the number of AEs per 
patient will be reported by trial arm. The number of patients with any AE will be compared 
by chi-squared test between arms. 
Levels of adherence to study treatment will be presented descriptively (means and SDs, as 
well as grouped as ≥80% (strong adherence), <80% but ≥50% (moderate adherence) and 
<50% (poor adherence)). Compliers will be defined as those having taken any dose of 
medication on 80% or more of the prescribed days. Patients with missing data at 5 weeks 
will be assumed to be noncompliant with the trial regimen.  
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Sensitivity analyses 
Sensitivity analyses will include: (i) primary analysis adjusting for baseline level of 
dependence; (ii) primary analysis adjusting for baseline level of dependence, age, gender, 
form of tobacco use and any potentially influential baseline variables for which chance 
imbalances between groups may have been observed; and (iii) an appropriate repeat of the 
primary analysis that takes treatment adherence into account.  
Subgroup analyses 
The primary logistic regression analysis will be repeated including a treatment by subgroup 
interaction for six sub-groups, collected at baseline: (i) tobacco use (smoked only, smoked 
and smokeless), (ii) gender (male, female), (iii) age (<40, ≥40), (iv) TB severity (I to IV), (v) 
SES (percentile cut-off of a wealth index derived from education/household assets/work 
status) and (vi) country (Pakistan, Bangladesh). Abstinence rates, risk differences and 
relative risk for each sub-group will be reported with 95% CIs. P-values for the interaction 
terms will be reported; however, the trial is not powered to detect interactions. 
Cost-effectiveness analysis 
In order to undertake a full cost-effectiveness analysis (CEA), costs of the interventions and 
participants’ use of wider health care (e.g. doctor visits, hospital attendances etc.) will be 
collected for both groups. Basic unit costs collected alongside the trial will then be applied 
to complete health care cost profiles. The costs of patients’ TB-related care will be included 
in the service-use questionnaires and costs allocated accordingly. Two outcomes will be 
used for the CEA; quitters (primary outcome) and Quality Adjusted Life-Years (QALYs), 
calculated from the EQ-5D-5L (a measure of health utility) collected during the trial (35). 
We will calculate incremental cost-effectiveness ratios (ICER) combining treatment and 
wider health care costs with each outcome.  
Bootstrapping techniques will be employed and cost-effectiveness planes and cost-
effectiveness acceptability curves will be constructed to reflect any uncertainty in the results 
and threshold. The CEA will demonstrate the value for money of adding cytisine to BS from 
the perspective of the service provider (the public or voluntary sector). We will also 
estimate the wider societal cost to patients, with a supporting analysis presenting the costs 
to patients incurred from out-of-pocket payments, productivity loss and travel costs. 
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DISCUSSION 
Our trial is innovative and important in several ways. To our knowledge, this is the only 
pragmatic RCT investigating the safety, effectiveness and cost-effectiveness of cytisine for 
smoking cessation in LMICs and in TB patients. It is also, so far, the largest trial of cytisine 
in the world. Despite an overwhelming case for providing cessation support to TB patients 
(36), this has generally not been done. Lack of evidence on cheap and effective solutions has 
been a significant barrier. For those living in LMICs, it may be considered less expensive to 
continue smoking than to purchase smoking cessation medications (19). Cytisine, if proven 
effective, can offer a cheaper alternative to other cessation aids. Furthermore, because 
cytisine is a plant-based medication, adherence may be better than with synthetic products. 
It may fit well with certain cultures blending traditional approaches with western-style 
medicine.  
The current evidence on the effectiveness of smoking cessation interventions, based on quit 
rates, has had limited success in convincing TB managers to include these in routine TB 
care. Our trial will test the impact of smoking cessation on TB outcomes - a key strength of 
this study. This could provide leverage to include cessation within routine TB care. 
Identifying cost-efficient means to influence TB and tobacco - the two converging epidemics 
- could benefit policy directions in the area (37).  
Our trial is conducted in Pakistan and Bangladesh where smokeless tobacco use is common. 
With any efforts towards encouraging people to quit smoking, there are always concerns 
that people may quit smoking but switch to smokeless tobacco. A unique feature of this 
study is that it can assess any substitution between smoking and smokeless tobacco. 
The study’s results will need to be considered in the light of some caveats, including some 
anticipated risks. Trial participants’ adherence with the complicated dose regime of cytisine 
could be a potential issue. While we will assess adherence with cytisine using a number of 
self-reported measures, we are concerned that participating TB patients may find it 
challenging to take cytisine (with its frequent dosing schedule) along with their TB 
treatment. Given that ours is an effectiveness trial, any attempts to increase adherence are 
limited to what is feasible in the real world. It is also important to acknowledge that if BS is 
not delivered or is not as effective as in previous trials then cytisine may have lesser (or 
greater) impact. Secondly, the study is not statistically powered to detect any differences 
between the two arms for TB outcomes. However, we can provide estimates for future 
research on TB outcomes by quit status in the cohort. We will also use our data for a future 
cumulative meta-analysis to ascertain effectiveness of such interventions on TB outcomes.   
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Lastly, although cytisine has been used in Eastern Europe and in New Zealand, it has not 
been used in a study in South Asia (Tropical climate zone) and its stability and 
pharmacovigilance have not been tested in the temperatures and humidity encountered in 
this zone. Although we will control the storage conditions of cytisine for the study within 
the manufacturer’s recommended range, there is a need for a pharmacovigilance study of 
cytisine to establish its stability under different climatic conditions. 
A placebo-controlled trial of cytisine raises some questions on the ethics of depriving at 
least 50% patients of a treatment that has some good evidence of its efficacy. On the other 
hand, all trial participants are offered behaviour support with specific advice for patients on 
how to quit, with the leaflet as an additional resource to take home. Besides, in the current 
scenario, TB patients who smoke have almost no chance of getting any smoking cessation 
medication; in our trial they have at least 50% chance. Furthermore, the evidence on the 
efficacy of cytisine is still not completely established. 
Retention and dropout is a key issue for all smoking cessation trials. Nonetheless, we will 
ensure that, where possible, retention remains high. To our advantage, the trial participants 
will have most of their follow-ups in line with their routine TB treatment visits. However, 
higher attrition rates are anticipated once TB treatment is completed. We will set up 
follow-up reminders (text messages or phone calls) and home visits for patients who are 
unable or unwilling to visit the trial sites.  
To summarise, if cytisine is found to be effective, it will be an affordable option for policy 
makers in LMICs to consider when including smoking cessation in TB programmes. 
OTHER INFORMATION 
Trial governance 
Ethics approval 
The trial has been granted ethics approval by the Health Sciences Research Governance 
Committee (HSRGC) at the University of York, UK, by the National Bioethics Committee, 
Pakistan Medical Research Council (Ref: No.4-87/16/NBC-200 Part-B/RDC/4197), and by 
the National Research Ethics Committee, Bangladesh Medical Research Council (Ref: 
BMRC/NREC/2016-2019/1475). As cytisine is not licensed for use in either country, 
approvals were obtained from the Drug Regulatory Authority of Pakistan (1st December 
2016) and the Directorate General of Drug Administration in Bangladesh (21st March 
2017). 
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Oversight committees 
Trial oversight committees include an Independent Steering Committee (ISC), an 
independent Data Monitoring and Ethics Committee (DMEC) and the Trial Management 
Team (TMG). Only the DMEC will have access to the unblinded comparative data from the 
trial. The study will be stopped, as guided by the ISC and DMEC, if: (i) new literature 
indicates findings that can be applied to this question in terms of benefit or side effects. 
However, early evidence of clear benefit would not be a reason to halt recruitment in the 
trial because data on TB outcomes would still be useful for the full sample size. (ii) reporting 
of AEs indicates that review of the study protocol is required, for the study medication. 
Dissemination policy 
Results will be disseminated to key stakeholders and patients in several ways. These 
include; open access peer-reviewed journal articles; presentation at key scientific meetings; 
posting on the study website; feedback to trial participants; press releases at collaborating 
Universities. We will explore non-academic routes to dissemination, for example through 
the NTPs in Bangladesh and Pakistan. 
The findings of the TB & Tobacco trial will be made public (after academic publication), in 
accordance with the requirements of the funder (EU) and Addiction journal. We are 
committed to share our behavioural support intervention materials and the related training 
packages at the end of the study. Requests for access to data and code will be reviewed by 
the study Chief Investigator and confirmed with the sponsor (University of York).   
The criteria for authorship will be taken from the International Committee of Medical 
Journal Editors (38). 
Trial status 
The current HSRGC approved protocol is version 3.0 (24 March 2017). This manuscript is 
a re-structured and edited version of the current approved protocol, to comply with the 
CONSORT reporting guidelines. The first patient was recruited into the trial on 06 June 
2017 in Pakistan and 22 July 2017 in Bangladesh. Recruitment is anticipated to be complete 
by the end of May 2018. 
Funding 
This study is funded by the European Commission under the Research and Innovation 
action, H2020-HCO-2015 Funding scheme (grant number 680995). 
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FIGURES AND TABLES WITH LEGENDS  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*MDR- Multi-Drug Resistant; **PASA- Para Amino Salicylic Acid; ŧ PTB - Pulmonary Tuberculosis; § MUAC - Mid Upper Arm Circumference 
Figure 1. TB & Tobacco trial flowchart 
 
No consent: 
- Complete Screening Form 
Dispense medicine 
 7 days’ supply of medication 
Complete CRF 
 Socio-Demographic, Tobacco use & Quit history 
 Nicotine Dependence  
 TB outcomes (clinical score, sputum, X-ray, treatment adherence) 
 Economic evaluation 
Measure 
 Height and Weight 
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 Visit (Day 5 [+2]) 
Dispense medicine 
 18 days’ supply of medicine 
Complete CRF 
 Medicine adherence 
 Adverse events review 
 Process evaluation 
 
 
Visit (Week 5 [+5]) 
Measure 
 Height and Weight 
 MUAC 
Complete CRF  
 Self-reported tobacco use status 
 TB outcomes (clinical score, sputum) 
 Medicine adherence 
 Adverse events review 
 Nicotine Dependence  
 
 
 
Visit (Day 0) 
Newly diagnosed PTBŧ patients who 
smoke tobacco on a daily basis 
Consent:  
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Randomise  
(contact country 
office) 
Inclusion criteria: 
 Adults  
 Diagnosed with PTB in last 4 
weeks  
 Smokes tobacco on a daily basis 
(with or without smokeless tobacco) 
 Willing to quit tobacco use 
 Able to provide consent 
Exclusion criteria: 
 Diagnosed with retreatment, MDR*, 
Miliary or extra-pulmonary TB 
 On treatment with streptomycin and/ 
or PASA** 
 Current user of tobacco dependence 
pharmacotherapy 
 Cytisine contraindications: myocardial 
infarction, stroke, or severe angina 
attack within the last 2 weeks, 
uncontrolled hypertension, severe 
renal impairment, schizophrenia or 
known diagnosis of epilepsy, 
pregnant/lactating or planning 
pregnancy 
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Measure 
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 MUAC 
Complete CRF  
 TB outcomes (clinical score, sputum, X-ray, treatment adherence) 
 Adverse events review 
 Nicotine Dependence  
 
Not eligible: 
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 TB outcomes (clinical TB score) 
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 TB outcomes (clinical score, sputum, X-ray, programme & adherence) 
 Nicotine Dependence  
 Economic evaluation 
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Table 1. TB* & Tobacco objectives 
Primary objective 
a. To evaluate the effectiveness and cost-effectiveness of cytisine for smoking cessation among TB 
patients who smoke on a daily basis 
Secondary objectives 
b. To assess the effectiveness and cost-effectiveness of cytisine  in improving the clinical outcomes of TB 
patients who smoke tobacco 
c. To assess any differences in the effectiveness by the form of tobacco used (tobacco smoking only 
versus a combination of smoking and smokeless tobacco) 
d. To assess any differences in the effect across different TB severity groups, high and low socio-
economic status (SES), gender and age sub-groups 
e. To translate for use in the target population and assess psychometric properties (validity and 
reliability) of the Mood and Physical Symptoms Scale (MPSS) for the assessment of withdrawal 
symptoms, and the Strength of Urges to Smoke (SUTS) for the assessment of nicotine  dependency 
f. To assess adverse effects of cytisine in the target population 
g. To assess all relevant components of the design and delivery of the smoking cessation programme as 
part of a process evaluation 
*TB = tuberculosis  
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Table 2. Patient eligibility criteria 
Inclusion Criteria 
a. Age at least 15 years in Pakistan and 18 years in Bangladesh (definitions of adult TB* patients in the 
two countries)  
b. Able to provide consent 
c. Diagnosed with pulmonary TB (smear positive or negative) in the last four weeks  
d. Currently smokes tobacco on a daily basis (with or without smokeless tobacco use) 
e. Willing to quit tobacco use  
Exclusion criteria 
a. Retreatment TB, MDR TB, Miliary or Extra-pulmonary TB 
b. Currently receiving Streptomycin (Category II anti-TB medication) and/or Para Amino Salicylic Acid 
(PASA) ** 
c. Currently using any pharmacotherapy for tobacco dependence  
Cytisine contraindications: 
d. Pregnant, lactating, or planning to become pregnant 
e. Had myocardial infarction, stroke, or an attack of severe angina within the previous two weeks 
f. Uncontrolled high blood pressure despite being on medication  
g. Severe renal impairment (requiring dialysis) 
h. Suffering from schizophrenia or known to be diagnosed with epilepsy 
*TB = tuberculosis  
** Using cytisine with anti-TB medicines (PASA, streptomycin) reduces stimulant action of cytisine (39)  
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Table 3. Dosing schedule of cytisine and packing details 
Day of treatment Intake interval 
(1 to 6 capsules daily over a period 
of 12 waking hours) 
Total daily capsules 
(number included in each packet) 
Day 1-3 1 capsule every 2 hours 6 capsules daily (6x3=18 capsules per packet) 
Day 4-7 1 capsule every 2.5 hours 5 capsules daily (5x4= 20 capsules per packet) 
Day 8-12 1 capsule every 2.5 hours 5 capsules daily (5x5= 25 capsules per packet) 
Day 13-16 1 capsule every 3 hours 4 capsules daily (4x4= 16 capsules per packet) 
Day 17-20 1 capsule every 4 hours 3 capsules daily (3x4= 12 capsules per packet) 
Day 21- 24 1 capsule every 6 hours  2 capsules daily (2x4= 8 capsules per packet) 
Day 25 1 capsule on the last day 1 capsule on the last day 
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Table 4. Schedule of enrolment and follow-up assessments for TB & Tobacco trial 
ASSESSMENT STUDY PERIOD 
Time point  
Day 0  Day 5 Week 5 
(Day 
35)  
Week 9  
(Day 63)  
Week 12 
(Day 84)   
Month 6 
(Week 
25) 
Month 12 
(Week 52) 
Allowed variation in days   -/+2 days -/+5 days 
Eligibility screen x       
Informed consent x       
Randomisation x       
Tobacco use (self-reported) x  x  x x x 
Socio-demographic history§ x       
Tobacco use and quit 
history⫮  
x       
Nicotine dependence⫝  x  x  x x x 
Economic outcomes x     x x 
Process outcomes x x      
Tobacco use (biochemical 
measures) 
     x x 
Study medication 
dispensing 
x 
(for 7 days) 
x 
(for 18 days) 
     
Medication adherence  x x     
Adverse events review 
(checklist) 
 x x x    
Clinical TB* score x  x x x x x 
TB sputum conversion  x  x x  x x 
TB chest X-ray grading x   x  x x 
TB treatment adherence x   x  x  
TB treatment outcomes      x x 
*TB = tuberculosis; § Socio-demographic history includes: age, gender, marital status, household assets, education, work status; 
⫮ Tobacco use and quit history includes: initiation, duration, type, frequency and quantity of tobacco use, smoking restrictions inside 
homes, number of quit attempts, last quit attempt and duration of longest quit attempt; ⫝  Nicotine dependence includes: Mood and 
Physical Symptoms Scale, Strength of Urges to Smoke scale and Heaviness of Tobacco use Index. 
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Table 5. Smoking cessation outcomes: primary and secondary measures.  
Outcome Definition 
Primary outcome 
measure: 
Continuous abstinence  
(at 6 months) 
Self-report of not using more than five cigarettes/bidis/water pipe 
sessions/chewing tobacco products from the quit date (5 +/- 2 days) to the 
reporting date, supported by a negative biochemical test at 6 months 
Secondary outcome 
measures: 
Continuous abstinence  
(at 12 months) 
 
Self-report of not using more than five cigarettes/bidis/water pipe 
sessions/chewing tobacco products from the quit date (5 +/- 2 days) to the 
reporting date, supported by a negative biochemical test at 12 months 
Point abstinence Self-report of not using tobacco in the previous 7 days, assessed at weeks 5 and 
12, and at months 6 and 12 
Early-lapse  Self-report of tobacco use (even once) after the quit date but having point 
abstinence at week 5 
Late-lapse Self-report of tobacco use (even once) between week 5 and week 12 but showing 
point abstinence at week 5 and week 12 
Early-relapse Abstinence at week 5 but a self-report of tobacco use by week 12 
Late-relapse Abstinence at week 5 and week 12 but a self-report of tobacco use by month 6 
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Table 6. TB outcomes 
Outcome Definition 
TB* score TB score consists of the following clinical signs and symptoms of TB: cough, chest pain, 
dyspnoea, anaemia, BMI <18 kg/m2, MUAC < 220 mm.  Each of the six clinical 
variables contributes 1 point, and BMI and MUAC contribute an extra point if < 16 
kg/m2 and < 200 mm, respectively, hence the maximum score of 8. Assessments for TB 
score are at day 0, week 5, 9 and 12 and at months 6 and 12. The TB score will be 
categorised into four severity classes (I to IV): SC I <2 points, SC II 2-3 points, SC III 4-
7 points and SC IV >7 points (27).  
Sputum 
conversion 
Sputum conversion results obtained at weeks 5 and 9 and at months 6 and 12, from 
routine TB laboratory testing. 
Chest X-ray 
grading 
Chest X-rays reports obtained at day 0, week 9 and months 6 and 12 graded according 
to the National Tuberculosis Association of the USA Grades by a senior radiologist will 
be categorised into four grades as 0 (normal), 1 (mild), 2 (moderate) and 3 (far advanced 
TB) (40). 
Treatment 
adherence  
TB patient’s medication logs (for anti-TB medication) consulted from routine TB cards 
will provide adherence assessments at day 0, week 9 and month 6. 
Programme 
outcomes 
Programme outcomes, as defined (41) below, recorded from routine TB registers at 
month 6. Additionally, relapse assessed at month 12 follow-up.   
Cured: ‘A patient who was initially smear-positive and who was smear negative 
in the last month of treatment (at month 6) and on at least one previous 
occasion’  
Completed treatment: ‘A patient who completed treatment (at month 6) but did 
not meet the criteria for cure or treatment failure’  
Treatment failure: ‘A patient who was initially smear-positive and who remained 
smear-positive at month 5 or later during treatment’  
Defaulted: ‘A patient whose treatment was interrupted for 2 consecutive months 
or more’  
Died: ‘A patient who died from any cause during treatment’  
Relapsed: ‘A patient who was previously treated for TB, was declared cured or 
treatment completed at the end of his most recent course of treatment, and is 
now diagnosed with a recurrent episode of TB (either a true relapse or a new 
episode of TB caused by reinfection)’ 
*TB = tuberculosis  
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Table 7. Definitions of adverse events 
Term Definition 
Adverse Event (AE) Any untoward medical occurrence in a patient to whom an IMP has been 
administered including occurrences that are not necessarily caused by or 
related to that product. 
Adverse Reaction (AR) Any untoward and unintended response to an IMP related to any dose 
administered. 
Unexpected Adverse 
Reaction (UAR) 
An adverse reaction, the nature or severity of which is not consistent with the 
information about the medicinal product in question set out in the SPC for 
that product, patient information leaflet, IB or protocol. 
Serious Adverse Event 
(SAE) or Serious Adverse 
Reaction (SAR) or 
Suspected Unexpected 
Serious Adverse Reaction 
(SUSAR)  
Respectively any adverse event, adverse reaction or unexpected adverse 
reaction that: 
▪ Results in death 
▪ Is life-threatening* 
▪ Requires hospitalisation or prolongation of existing 
hospitalisation** 
▪ Results in persistent or significant disability or incapacity 
▪ Consists of a congenital anomaly or birth defect 
*The term life-threatening in the definition of a serious event refers to an event in which the patient is at risk of death at 
the time of the event; it does not refer to an event that hypothetically might cause death if it were more severe, for 
example, a silent myocardial infarction.  
**Hospitalisation is defined as an inpatient admission, regardless of length of stay, even if the hospitalisation is a 
precautionary measure for continued observation. Hospitalisations for a pre-existing condition, that has not worsened 
or for an elective procedure do not constitute an SAE. 
 
